Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection

被引:119
作者
Namour, Florence [1 ]
Diderichsen, Paul Matthias [2 ]
Cox, Eugene [2 ]
Vayssiere, Beatrice [1 ]
Van der Aa, Annegret [3 ]
Tasset, Chantal [3 ]
Van't Klooster, Gerben [3 ]
机构
[1] Galapagos SASU, F-93230 Romainville, France
[2] Quantitat Solut BV, NL-4818 SJ Breda, Netherlands
[3] Galapagos NV, B-2800 Mechelen, Belgium
关键词
RHEUMATOID-ARTHRITIS;
D O I
10.1007/s40262-015-0240-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objectives Filgotinib (GLPG0634) is a selective inhibitor of Janus kinase 1 (JAK1) currently in development for the treatment of rheumatoid arthritis and Crohn's disease. While less selective JAK inhibitors have shown long-term efficacy in treating inflammatory conditions, this was accompanied by dose-limiting side effects. Here, we describe the pharmacokinetics of filgotinib and its active metabolite in healthy volunteers and the use of pharmacokinetic-pharmacodynamic modeling and simulation to support dose selection for phase IIB in patients with rheumatoid arthritis. Methods Two trials were conducted in healthy male volunteers. In the first trial, filgotinib was administered as single doses from 10 mg up to multiple daily doses of 200 mg. In the second trial, daily doses of 300 and 450 mg for 10 days were evaluated. Non-compartmental analysis was used to determine individual pharmacokinetic parameters for filgotinib and its metabolite. The overall pharmacodynamic activity for the two moieties was assessed in whole blood using interleukin-6-induced phosphorylation of signal-transducer and activator of transcription 1 as a biomarker for JAK1 activity. These data were used to conduct non-linear mixed-effects modeling to investigate a pharmacokinetic/pharmacodynamic relationship. Results Modeling and simulation on the basis of early clinical data suggest that the pharmacokinetics of filgotinib are dose proportional up to 200 mg, in agreement with observed data, and support that both filgotinib and its metabolite contribute to its pharmacodynamic effects. Simulation of biomarker response supports that the maximum pharmacodynamic effect is reached at a daily dose of 200 mg filgotinib. Conclusion Based on these results, a daily dose range up to 200 mg has been selected for phase IIB dose-finding studies in patients with rheumatoid arthritis.
引用
收藏
页码:859 / 874
页数:16
相关论文
共 13 条
[1]  
Beal S. L., 1989, NONMEM USERS GUIDES
[2]  
EMEA, 2007, Guideline on reporting the results of population pharmacokinetic analyses
[3]  
Galien R, 2013, ARTHRITIS RHEUM SUPP, V10, P478
[4]   Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550) [J].
Ghoreschi, Kamran ;
Jesson, Michael I. ;
Li, Xiong ;
Lee, Jamie L. ;
Ghosh, Sarbani ;
Alsup, Jason W. ;
Warner, James D. ;
Tanaka, Masao ;
Steward-Tharp, Scott M. ;
Gadina, Massimo ;
Thomas, Craig J. ;
Minnerly, John C. ;
Storer, Chad E. ;
LaBranche, Timothy P. ;
Radi, Zaher A. ;
Dowty, Martin E. ;
Head, Richard D. ;
Meyer, Debra M. ;
Kishore, Nandini ;
O'Shea, John J. .
JOURNAL OF IMMUNOLOGY, 2011, 186 (07) :4234-4243
[5]   Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors [J].
Haan, Claude ;
Rolvering, Catherine ;
Raulf, Friedrich ;
Kapp, Manuela ;
Drueckes, Peter ;
Thoma, Gebhard ;
Behrmann, Iris ;
Zerwes, Hans-Guenter .
CHEMISTRY & BIOLOGY, 2011, 18 (03) :314-323
[6]   Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis [J].
Neubauer, H ;
Cumano, A ;
Muller, M ;
Wu, H ;
Huffstadt, U ;
Pfeffer, K .
CELL, 1998, 93 (03) :397-409
[7]   Janus kinase inhibitors in autoimmune diseases [J].
O'Shea, John J. ;
Kontzias, Apostolos ;
Yamaoka, Kunihiro ;
Tanaka, Yoshiya ;
Laurence, Arian .
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 :111-115
[8]   JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease [J].
O'Shea, John J. ;
Plenge, Robert .
IMMUNITY, 2012, 36 (04) :542-550
[9]   Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes [J].
Riese, Richard J. ;
Krishnaswami, Sriram ;
Kremer, Joel .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2010, 24 (04) :513-526
[10]  
US FDA, 1999, GUID IND POP PHARM